Global Radionuclide Drug Conjugates (RDC) Market Strategic Research Report

Scope of the Report

The global Radionuclide Drug Conjugates (RDC) market size is predicted to grow from US$ 9,295 million in 2025 to US$ 14,850 million in 2032; it is expected to grow at a CAGR of 7.1% from 2026 to 2032.

Radionuclide-conjugated drugs (RCDs) are complex molecules for precise targeted therapy and diagnosis, composed of three core elements: a targeting ligand, a linker, and a radionuclide. Their mechanism of action is similar to a "biologically guided miniature nuclear bomb": the targeting ligand specifically recognizes and binds to biomarkers highly expressed on the surface of diseased cells such as tumors; the linker ensures the stability of the entire molecule; and the radionuclide acts as the "warhead," accumulating at the target site and releasing ionizing radiation energy such as alpha and beta particles to destroy tumor cells from within, or releasing gamma/positron rays for highly sensitive molecular imaging diagnosis. This design achieves precise, "visualized" targeting of diseases and is a prime example of the deep integration of nuclear medicine and targeted drug technology.

The field of RCDs is experiencing explosive growth, with a broad and clear development prospect. Future trends will focus on: first, target diversification and drug iteration, with RDCs targeting new targets such as CLDN18.2 and FAP rapidly entering clinical trials, and the development of better ligands. Second, the advancement of treatment paradigms: the highly promising alpha radionuclide therapy holds the potential to conquer more complex and drug-resistant solid tumors, becoming a core next-generation treatment method. Third, the deep integration of diagnosis and treatment: patient stratification and personalized dosage regimens based on precise imaging will become standard procedures, greatly improving treatment efficiency and safety. Fourth, technological platform innovation: more stable connectivity technologies, prodrug strategies, and combination therapies will continuously expand its application boundaries. Overall, RDC is evolving from a "powerful tool" for a few specific cancer types into an indispensable precision diagnosis and treatment platform in oncology and even some non-oncology diseases.

This report presents a comprehensive overview of the global Radionuclide Drug Conjugates (RDC) market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Targeted Ligands

• Small molecules
• Peptides
• Antibodies

Segment by Therapeutic Purposes

• Therapeutic RDCs
• Diagnostic RDCs

Segment by Decay Types

• Alpha Nuclide RDCs
• Beta Nuclide RDCs

Segment by Application

• Prostate Cancer
• Neuroendocrine Tumors
• Liver Cancer
• Kidney Cancer
• Bone Metastases
• Others

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Radionuclide Drug Conjugates (RDC) market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Prostate Cancer, Neuroendocrine Tumors, Liver Cancer evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact